Cargando…
Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer
BACKGROUND: The use of low-molecular-weight, non-peptidic molecules that disrupt the interaction between the p53 tumor suppressor and its negative regulator MDM2 has provided a promising alternative for the treatment of different types of cancer. Among these compounds, RITA (reactivation of p53 and...
Autor principal: | Espinoza-Fonseca, L Michel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243243/ https://www.ncbi.nlm.nih.gov/pubmed/16174299 http://dx.doi.org/10.1186/1742-4682-2-38 |
Ejemplares similares
-
On Rita Levi-Montalcini
por: Melino, Gerry, et al.
Publicado: (2013) -
The p53-Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells
por: Chuang, Hui-Ching, et al.
Publicado: (2014) -
First person – Rita Serrano
Publicado: (2022) -
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
por: Zhu, Haohao, et al.
Publicado: (2022) -
saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription
por: Portnoy, Victoria, et al.
Publicado: (2016)